Celularity Inc. (CELU)
NASDAQ: CELU · Real-Time Price · USD
0.7803
+0.0122 (1.59%)
At close: Jul 17, 2026, 4:00 PM EDT
0.7900
+0.0097 (1.24%)
After-hours: Jul 17, 2026, 7:57 PM EDT
Celularity Employees
Celularity had 115 employees as of December 31, 2025. The number of employees decreased by 8 or -6.50% compared to the previous year.
Employees
115
Change (1Y)
-8
Growth (1Y)
-6.50%
Revenue / Employee
$230,870
Profits / Employee
-$798,261
Market Cap
22.59M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 115 | -8 | -6.50% |
| Dec 31, 2024 | 123 | 3 | 2.50% |
| Dec 31, 2023 | 120 | -105 | -46.67% |
| Dec 31, 2022 | 225 | 0 | - |
| Dec 31, 2021 | 225 | 63 | 38.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| IGC Pharma | 70 |
| NextCure | 40 |
| Plus Therapeutics | 28 |
| NeuroSense Therapeutics | 17 |
| Quantum BioPharma | 17 |
| VYNE Therapeutics | 10 |
| Marker Therapeutics | 5 |
CELU News
- 26 days ago - Penny Stocks: Why Is Celularity (CELU) Stock Trending Today? - TipRanks
- 6 weeks ago - Celularity announces cenplacel-L availability for investigational use in Florida - TheFly
- 6 weeks ago - Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies - GlobeNewsWire
- 6 weeks ago - Celularity Releases CEO Letter to Shareholders - GlobeNewsWire
- 6 weeks ago - Celularity Appoints Rick Gonzalez as Chief Commercial Officer - GlobeNewsWire
- 7 weeks ago - Celularity Receives Nasdaq Notice Regarding Form 10-Q - GlobeNewsWire
- 2 months ago - Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation - GlobeNewsWire
- 2 months ago - Celularity Annual report: Q4 2025 - Filings